A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.
Also called NCT06797869
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 142 participants
- Sponsor
- Registry
-
NCT06797869
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Denmark, France, Norway, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06797869. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-29 (actual); primary completion 2026-06-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Diabetic Peripheral Neuropathy
- Intervention (Drug)
- CagriSema (Cagrilintide B and Semaglutide I)
- Intervention (Drug)
- Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06797869- Content hash
ef5fc21945788c9d9ed419832c8dc81688b8f8f7f6fc23d0163918975ecdace1